» Articles » PMID: 34305597

Untargeted LC/MS-Based Metabolic Phenotyping of Hypopituitarism in Young Males

Overview
Journal Front Pharmacol
Date 2021 Jul 26
PMID 34305597
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Hypopituitarism (Hypo-Pit) is partial or complete insufficiency of anterior pituitary hormones. Besides hormone metabolism, the global metabolomics in Hypo-Pit are largely unknown. We aimed to explore potential biomarkers to aid in diagnosis and personalized treatment. Using both univariate and multivariate statistical methods, we identified 72 differentially abundant features through liquid chromatography coupled to high-resolution mass spectrometry, obtained in 134 males with Hypo-Pit and 90 age matched healthy controls. Hypopituitarism exhibits an increased abundance of metabolites involved in amino acid degradation and glycerophospholipid synthesis, but decreased content of metabolites in steroid hormone synthesis and fatty acid beta-oxidation. Significantly changed metabolites included creatine, creatinine, L-alanine, phosphocholines, androstenedione, hydroprenenolone, and acylcarnitines. In Hypo-Pit patients, the increased ratio of creatine/creatinine suggested reduced creatine uptake and impaired creatine utilization, whereas the decreased level of beta-hydroxybutyrate, acetylcarnitine (C2) and a significantly decreased ratio of decanoylcarnitine (C10) to free carnitine suggested an impaired beta-oxidation. Furthermore, the creatine/creatinine and decanoylcarnitine/carnitine ratio were identified as diagnostic biomarkers for Hypo-Pit with AUCs of 0.976 and 0.988, respectively. Finally, we found that the creatinine and decanoylcarnitine/carnitine ratio could distinguish cases that were sensitive vs. resistant to human chorionic gonadotropin therapy. We provided a global picture of altered metabolic pathways in Hypo-Pit, and the identified biomarkers in creatine metabolism and beta-oxidation might be useful for the preliminary screening and diagnosis of Hypo-Pit.

Citing Articles

Effect of Growth Hormone on Branched-Chain Amino Acids Catabolism in Males With Hypopituitarism.

Zhang Y, Ye Z, Xiang E, Chen P, Fang X J Cell Mol Med. 2025; 29(5):e70451.

PMID: 40032645 PMC: 11875759. DOI: 10.1111/jcmm.70451.


Proteomic and metabolomic analysis of GH deficiency-induced NAFLD in hypopituitarism: insights into oxidative stress.

Zhang Y, Chen P, Fang X Front Endocrinol (Lausanne). 2024; 15:1371444.

PMID: 38836220 PMC: 11148278. DOI: 10.3389/fendo.2024.1371444.

References
1.
Krsek M . [Growth hormone, axis GH-IGF1 and glucose metabolism]. Vnitr Lek. 2016; 62(11 Suppl 4):S62-66. View

2.
Micic S, Lalic N, Djordjevic D, Bojanic N, Bogavac-Stanojevic N, Busetto G . Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia. 2019; 51(6):e13267. PMC: 6850469. DOI: 10.1111/and.13267. View

3.
Souto-Carneiro M, Toth L, Behnisch R, Urbach K, Klika K, Carvalho R . Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis. Ann Rheum Dis. 2020; 79(4):499-506. PMC: 7147174. DOI: 10.1136/annrheumdis-2019-216374. View

4.
Fischer S, Frederick A, Tran V, Li S, Jones D, Fridovich-Keil J . Metabolic perturbations in classic galactosemia beyond the Leloir pathway: Insights from an untargeted metabolomic study. J Inherit Metab Dis. 2019; 42(2):254-263. PMC: 6414239. DOI: 10.1002/jimd.12007. View

5.
Li Z, Chen G, Shang X, Bai W, Han Y, Chen B . [A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia]. Zhonghua Nan Ke Xue. 2005; 11(10):761-4. View